Trials / Unknown
UnknownNCT04155671
POF Versus FOLFOX Plus IP Paclitaxel in AGC
A Phase 2 Study of POF(Paclitaxel/Oxaliplatin/5-Fluorouracil/Leucovorin) Versus FOLFOX Plus Intraperitoneal Paclitaxel as a First-line Treatment in Advanced Gastric Cancer With Peritoneal Metastases
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 260 (estimated)
- Sponsor
- Fujian Cancer Hospital · Other Government
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study was to compare the efficacy and safety of intravenous or intraperitoneal paclitaxel plus FOLFOX as first-line treatment in AGC with peritoneal metastases, a phase II Clinical trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | POF | Paclitaxel plus Oxaliplatin plus Leucovorin plus 5-FU |
| DRUG | FOLFOX plus PAC(ip) | FOLFOX plus intraperitoneally paclitaxel |
Timeline
- Start date
- 2019-12-01
- Primary completion
- 2022-11-30
- Completion
- 2023-06-30
- First posted
- 2019-11-07
- Last updated
- 2019-11-07
Source: ClinicalTrials.gov record NCT04155671. Inclusion in this directory is not an endorsement.